GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Shanghai HeartCare Medical Technology Corp Ltd (HKSE:06609) » Definitions » Operating Income

Shanghai HeartCare Medical Technology (HKSE:06609) Operating Income : HK$-112.4 Mil (TTM As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Shanghai HeartCare Medical Technology Operating Income?

Shanghai HeartCare Medical Technology's Operating Income for the six months ended in Dec. 2023 was HK$-46.3 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-112.4 Mil.

Warning Sign:

Shanghai HeartCare Medical Technology Corp Ltd has never been profitable in the past 3 years. It lost money every year.

Operating Margin % is calculated as Operating Income divided by its Revenue. Shanghai HeartCare Medical Technology's Operating Income for the six months ended in Dec. 2023 was HK$-46.3 Mil. Shanghai HeartCare Medical Technology's Revenue for the six months ended in Dec. 2023 was HK$134.3 Mil. Therefore, Shanghai HeartCare Medical Technology's Operating Margin % for the quarter that ended in Dec. 2023 was -34.48%.

Shanghai HeartCare Medical Technology's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Shanghai HeartCare Medical Technology's annualized ROC % for the quarter that ended in Dec. 2023 was -15.22%. Shanghai HeartCare Medical Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -29.00%.


Shanghai HeartCare Medical Technology Operating Income Historical Data

The historical data trend for Shanghai HeartCare Medical Technology's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai HeartCare Medical Technology Operating Income Chart

Shanghai HeartCare Medical Technology Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Operating Income
-84.32 -244.60 -219.65 -207.13 -112.38

Shanghai HeartCare Medical Technology Semi-Annual Data
Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Operating Income Get a 7-Day Free Trial Premium Member Only -102.38 -87.08 -124.17 -66.09 -46.29

Shanghai HeartCare Medical Technology Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$-112.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Shanghai HeartCare Medical Technology  (HKSE:06609) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Shanghai HeartCare Medical Technology's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jun. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-92.582 * ( 1 - 17.83% )/( (516.83 + 482.62)/ 2 )
=-76.0746294/499.725
=-15.22 %

where

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1366.783 - 35.34 - ( 814.613 - max(0, 60.692 - 1130.644+814.613))
=516.83

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1313.896 - 42.509 - ( 788.767 - max(0, 65.388 - 1099.677+788.767))
=482.62

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Shanghai HeartCare Medical Technology's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jun. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-103.366/( ( (168.696 + max(194.325, 0)) + (109.024 + max(240.911, 0)) )/ 2 )
=-103.366/( ( 363.021 + 349.935 )/ 2 )
=-103.366/356.478
=-29.00 %

where Working Capital is:

Working Capital(Q: Jun. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(64.757 + 174.717 + 8.787) - (35.34 + 0 + 18.596)
=194.325

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(84.126 + 159.734 + 57.067) - (42.509 + 0 + 17.507)
=240.911

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Shanghai HeartCare Medical Technology's Operating Margin % for the quarter that ended in Dec. 2023 is calculated as:

Operating Margin %=Operating Income (Q: Dec. 2023 )/Revenue (Q: Dec. 2023 )
=-46.291/134.27
=-34.48 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Shanghai HeartCare Medical Technology Operating Income Related Terms

Thank you for viewing the detailed overview of Shanghai HeartCare Medical Technology's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai HeartCare Medical Technology (HKSE:06609) Business Description

Traded in Other Exchanges
N/A
Address
No. 356, Zhengbo Road, Floor 1 and 3, Building 38, Pilot Free Trade Zone, Lingang New District, Shanghai, CHN
Shanghai HeartCare Medical Technology Corp Ltd is an innovative neuro-interventional medical device company. The company is committed to creating high-quality products for the prevention and treatment of stroke. Geographically, the Group's revenue is derived from Mainland China.
Executives
Ding Kui 2201 Interest of corporation controlled by you
Wisary Limited 2101 Beneficial owner
Wang Guohui
Shanghai Zandaqian Enterprise Management Consulting Center
Lyfe Capital Management Limited
Lyfe Capital Fund Iii (dragon), L.p.
Shanghai Weiyun Enterprise Management Consulting Partnership (lp)
Lyfe Columbia River Limited
Temasek Holdings (private) Limited
Elbrus Investments Pte. Ltd.
Fullerton Management Pte Ltd
Temasek Life Sciences Private Limited

Shanghai HeartCare Medical Technology (HKSE:06609) Headlines

No Headlines